Marrow toxicity from chemotherapy or radiotherapy may be overcome by reconstituting the patient's hematopoietic capacity. In practice, allogeneic marrow transplantation has largely been limited to the leukemias. The article reviews clinical experience, emphasizing results with grafts, as well as major problems—relapse, GVHD, infection, and donor matching and availability.